Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

Alphabet’s Isomorphic Labs is preparing to begin the first human clinical trials of a drug designed with the help of artificial intelligence, according to company leadership. The UK-based firm ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

After years of development, Murdoch says human clinical trials for Isomorphic’s AI-designed drugs are finally within reach.

Expect AI-made prescription drugs to be ready for clinical trials in a couple of years, predicts Google DeepMind CEO By Sarah Jackson Andrew Brookes/Getty Images Feb 26, 2024, 1:11 PM PT ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis.

Google Cloud joins with biotech startups to accelerate AI-driven drug discovery and scientific research - SiliconANGLE [the voice of enterprise and emerging tech] search ...

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

Founder and Chief Executive Officer Demis Hassabis, who also leads Deepmind, suggested in January that Isomorphic Labs will have AI-designed drugs in clinical trials by the end of 2025.